Lea Ray is a certified director (ICD.D) of the Institute of Corporate Directors, a Chartered Professional Accountant and seasoned board director. She holds a Bachelor of Commerce Degree from the Odette School of Business, University of Windsor. Lea has served as the Chairman, Vice-chairman, Lead Independent Director and Audit Committee Chair on a variety of publicly-listed (TSX), public sector and non-profit entities. She is a former executive, Vice-President Corporate Finance, of Warner Bros. Entertainment Canada Inc. and former member of the Professional Conduct Committee of the Chartered Professional Accountants (Ontario).
Mr. Honeyman has served as CEO of FWT since 2015 and President since 2016. Mr. Honeyman has over 20 years of experience commercializing new technologies, having worked in senior or executive positions for both large multi-national companies including Cabot Corporation and more recently several innovation based start-ups, such as E Ink and Natrix Separations Inc. Mr. Honeyman has also served as the Chief Technology Officer for GreenCentre Canada. Mr. Honeyman’s experience in developing and commercializing new technologies includes e-paper displays while at E Ink and high capacity high through-put membranes for bioprocessing as a Senior Vice President of Natrix Separations Inc., the latter was acquired by MilliporeSigma Canada Co. Mr. Honeyman is also the inventor of record on over 50 US patents. Mr. Honeyman holds a Ph.D. in Chemistry from the University of Toronto.
Dr. Andrew Pasternak has served as director of FWT since 2020. Dr. Pasternak has over 24 years of experience directing early-stage companies with technology commercialization and product development activities in a wide variety of fields including chemistry, biotechnology, medical devices, drug discovery and instrumentation. Dr. Pasternak has managed multi-disciplined teams in both large and start-up company environments, directing commercial efforts that have resulted in numerous strategic partnerships, high margin service contracts and licensing agreements. Dr. Pasternak is currently the Executive Director at GreenCentre Canada after serving the company in various commercialization from September 2010 to August 2021. Dr. Pasternak has also previously directed research and commercialization at MDS Sciex Inc., Covalon Technologies Ltd, Protana Inc. and Transition Therapeutics Inc. Dr. Pasternak holds a Ph.D. in Bio-Chemical Engineering from Northwestern University as well as an MBA from the Rotman School of Business (University of Toronto). Dr. Pasternak is an accredited Professional Director and serves as a board member in several early stage and volunteer organizations.
Mr. Koehle has served as director of FWT since 2019. Mr. Koehle has over 8 years of experience supporting the commercialization of early-stage companies. Mr. Koehle’s experience includes working in industries such as environmental, transportation, information technology, food, and medical. Mr. Koehle is also the Principal and Managing Director of FirstLine Venture Partners Corporation, a privately held venture capital firm. Over the past 15 years, he has served on numerous boards in both corporate and not-for-profit sectors. Mr. Koehle holds as B.A.Sc. in Mechanical Engineering from the University of Waterloo.
Mr. Gerald (Gerry) Goldberg CPA has over 40 years of experience working as an accountant and auditor. Mr. Goldberg is currently the Chief Executive Officer of Golden Hills Financial Inc. Mr. Goldberg was previously a senior partner at the accounting firm Schwartz Levitsky Feldman LLP and has served as the Chief Executive Officer of Canada House Wellness Group Inc. and Osoyoos Cannabis Inc (now Aion Therapeutics Inc). Mr. Goldberg has also previously served as the Chief Financial Officer of Capricorn Business Acquisitions Inc. (now Computational Unlimited Corp.) Mr. Goldberg’s experience also includes serving as a board member to both TSX, TSXV, CSE, NASDAQ, AMEX, and OTC.QB listed companies, including Pinetree Capital Ltd.(TSX); Capricorn Business Acquisition Inc (now Computational Unlimited Corp) (TSX.V); Grasslands Entertainment Inc. (now Lakeside Minerals Inc.) (TSXV); Baymount Incorporated
(formerly Academy Capital Corp.) (NEX); Sagittarius Capital Corporation (NEX); Jite Technologies Inc. (Delisted); Scorpio Capital Corp. (now Prime City One Capital Corp.) (TSXV); Leo Acquisitions Corp (now PsyBio therapeutics Corp.) (TSX.V); China Winds Systems Inc.(OCT.QB); Ever-Glory International Group Inc. (AMEX); Keyuan Petrochemical Inc. (OTC.QB); Emerge Resources Corp. (now Vaxil Bio Ltd) (NEX); Canada House Wellness Group Inc. (formerly ABBA Medix Group Inc.) (CSE); Gravitas Financial Inc. (CSE); Gilla Inc. (OTC.QB); FSD Pharma Inc. (CSE and NASDAQ). Osoyoos Cannabis Inc. (now Aion Therapeutics Inc.) (CSE); SB2 Insights Inc. (CSE). Mr. Goldberg has also served as the audit committee chairman for most of the companies listed above both in Canada and the US. Mr. Goldberg holds a CPA from the Canadian Institute of Charter Accountants as well as a Certificate in the Theory of Accounting from the University of South Africa.
Dr. Maddever has served as director of FWTC since 2020. Dr. Maddever has over 35 years of experience working in senior executive management positions with technically based businesses in start-up, turnaround or acquisition situations where his skills at change management have aided in the commercialization of new technologies. Dr. Maddever’s experience in both private and public companies, both domestically and internationally, spans a broad variety of industries, including bio- and advanced materials, precision manufacturing, recycling, waste to energy and medical devices. Dr. Maddever is currently Portfolio Manager at Bioindustrial Innovation Canada and a Fellow of the Canadian Academy of Engineering. Dr. Maddever also holds a number of patents in several fields. Dr. Maddever holds a Ph.D. in Materials Science Engineering from the University of Toronto.